Company / FCF Margin
Ernexa Therapeutics Inc. FCF Margin History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-2784.4%
FY2025
5-year range
-30039.7% / 9.0%
FY2021-FY2025
Trend
+90.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has fluctuated over the past 9 years, ranging from -30039.7% in FY2024 to 9.0% in FY2020.
Based on SEC 10-K filings.
-2784.4% in FY2025 with a 10-year CAGR of -2756.6%.
Declined from 9.0% to -2784.4% over the past 5 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -2793.3pp
- 10-Year Change
- -2756.6pp
Key checks
Key Insights
- In FY2025, fcf margin increased 90.7% year-over-year.
- Peak fcf margin was recorded in FY2020.
- Lowest fcf margin in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -2784.4% | +90.7% |
| FY2024 | -30039.7% | - |
| FY2023 | - | - |
| FY2020 | 9.0% | +192.5% |
| FY2019 | 3.1% | +465.5% |
| FY2018 | -0.8% | +53.6% |
| FY2017 | -1.8% | +91.4% |
| FY2016 | -21.1% | +23.9% |
| FY2015 | -27.7% | -1142.1% |
| FY2014 | 2.7% | -31.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026